5 Best Small-Cap Healthcare Stocks To Buy Now

In this article, we discuss 5 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 12 Best Small-Cap Healthcare Stocks to Buy Now. 

5. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Number of Hedge Fund Holders: 21

Market Capitalization as of December 12: $1.904 Billion

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a Maryland-based biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company posted a Q3 revenue of $177.35 million, up 19.4% year-over-year, beating market consensus by $4.87 million. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) raised its full-year 2022 total revenue guidance to $650 million-$680 million, from $640 million-$680 million previously. It is one of the best healthcare stocks to invest in. 

On October 11, Piper Sandler analyst David Amsellem maintained an Overweight rating on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) but lowered the price target on the shares to $36 from $38. The company received a complete response letter from the FDA for SPN-830, its subcutaneous continuous apomorphine infusion pump, in patients with advanced Parkinson’s disease, the analyst told investors. The positive news was that the FDA did not voice any concerns about safety or efficiency, but “not-so-good news” was that the agency did cite chemistry, manufacturing, and control issues with the underlying device and drug product, said the analyst. He believes the letter “portends a significant delay,” though he assumes that the issues are eventually fixable.

According to Insider Monkey’s Q3 data, 21 hedge funds were bullish on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), compared to 19 funds in the earlier quarter. Steven Boyd’s Armistice Capital is the largest position holder in the company, with 4.6 million shares worth $155.4 million. 

Here is what Third Avenue Management specifically said about Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in its Q2 2022 investor letter:

“Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will be highlighted in a future letter. Supernus was a notable healthcare investment as Fund Management has struggled to find investments in the Healthcare sector given stretched valuations. With the Healthcare sector down nearly 30% YTD, it provided an opportunity to add a healthcare company to the Fund.”